These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16483973)

  • 1. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].
    Johansen JK; Lose G
    Ugeskr Laeger; 1999 Nov; 161(44):6052-5. PubMed ID: 10778341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy.
    Buyse G; Verpoorten C; Vereecken R; Casaer P
    Eur J Pediatr Surg; 1995 Dec; 5 Suppl 1():31-4. PubMed ID: 8770576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
    Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
    J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.
    Salvatore S; Khullar V; Cardozo L; Milani R; Athanasiou S; Kelleher C
    Eur J Obstet Gynecol Reprod Biol; 2005 Apr; 119(2):237-41. PubMed ID: 15808387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
    Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
    J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
    Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J
    Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravesical treatment of overactive bladder syndrome].
    Haferkamp A; Hohenfellner M
    Urologe A; 2006 Oct; 45(10):1283-8. PubMed ID: 16972089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 15. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
    Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
    Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.
    Karademir K; Baykal K; Sen B; Senkul T; Iseri C; Erden D
    Scand J Urol Nephrol; 2005; 39(3):230-3. PubMed ID: 16118096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

  • 18. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
    Madersbacher H; Jilg G
    Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics.
    Kuo HC
    BJU Int; 2005 May; 95(7):1023-7. PubMed ID: 15839924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.